HOME >> MEDICINE >> NEWS
Tacrolimus Stops Rejection Of Kidney Transplants

The drug tacrolimus (also known as FK506) can halt or reverse unmanageable rejection of transplanted kidneys in three out of four cases says a report from 13 of the country's leading transplant centers.

Despite tremendous progress in regulating the immune system, stubborn or "refractory" rejection-an unrelenting immune system assault against the transplanted organ-remains one of the principal problems of organ transplantation. This is the first multi-center trial to demonstrate such encouraging results for persistent kidney rejection.

The study, which involved 73 patients who entered the trial between September, 1993, and May, 1994, is reported in the September 15, 1996, issue of Transplantation.

Tacrolimus rescue therapy, concluded the authors, provides prompt, effective reversal of refractory kidney rejection, good long-term kidney function, a low incidence of repeat rejection, and an acceptable safety profile.

"Our consistent success in reversing the worst-of-the-worst cases means that tacrolimus has become our preferred treatment for patients who experience refractory rejection following a kidney transplant," said the paper's lead author transplant surgeon E. Steve Woodle, M.D., from the University of Chicago Medical Center.

"Since uncontrolled rejection remains a primary cause of organ loss, this is a significant advance for our patients," he added.

Although about half of kidney transplant patients will experience at least one episode of rejection, a temporary boost in their medications-increased doses of corticosteroids or anti-lymphocyte antibodies-can usually bring the rejection under control.

About 10 to 15 percent of patients, however, experience uncontrollable or repeated bouts of rejection. These patients require additional therapy; however, the side effects of repeated courses of standard antirejection therapies-increased risk for infections or for a form of lym
'"/>

Contact: John Easton
jeaston@mcis.bsd.uchicago.edu
312-702-6241
University of Chicago Medical Center
15-Sep-1996


Page: 1 2

Related medicine news :

1. Tacrolimus + mycophenolate mofetil & steroids: Safe, effective in preventing acute cardiac rejection
2. Infants To Seniors: Seven Years Follow-Up Of 1,000 Liver Transplant Patients Taking Tacrolimus Indicates Children Have Best Survival
3. Liver Rejection Can Be Managed Long-Term In Children Switched To Tacrolimus
4. NIAID Stops AIDS Study Prematurely Because Drug Cocktail Boosts Survival
5. Rejection really hurts, UCLA psychologists find
6. Therapy Developed At Cedars-Sinai Medical Center Shows Promise In Preventing Rejection Of Transplanted Organs
7. Bone Marrow With Heart And Lung Transplants Reduces Rejection Of Transplanted Organs, Reports University Of Pittsburgh
8. Bone Marrow With Organ Transplants Reduces Rejection Of Transplanted Organs, Reports University Of Pittsburgh
9. Organ Rejection Drug Also Shows Promise For The Treatment Of Kidney Disease
10. Kidney cancer surgery safer at high-volume hospitals
11. Kidney transplant patients who develop diabetes show poor short-term outcomes

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/3/2020)... ... September 03, 2020 , ... BluePearl Specialty and Emergency ... Prevention’s (AFSP) annual signature event, Out of the Darkness (OOTD), which unites more ... raise awareness of suicide prevention. To ensure Associate safety, BluePearl will not be ...
(Date:9/3/2020)... ... 2020 , ... International Dark-Sky Association (IDA) recently bestowed the ... This advanced LED wireless dimming controller, along with the previously IDA approved Dimulator, ... against light pollution. Leo Smith, the Northeast Regional Director for IDA says “We ...
(Date:9/1/2020)... ... ... Feeding Matters , the first organization in the world dedicated to advancing the ... that the U.S. Centers for Disease Control and Prevention (CDC) has officially approved PFD ... U.S. International Classification of Diseases (ICD ) on October 1, 2021. ...
(Date:8/31/2020)... (PRWEB) , ... August 31, 2020 , ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – today announced the 10th Anniversary of Blood Cancer Awareness Month (BCAM) ...
(Date:8/31/2020)... ... August 31, 2020 , ... ... solution for chiropractors, announced today the launch of its integrated, HIPAA compliant, telehealth ... running their virtual practice in under 90 seconds. , According to the ...
Breaking Medicine News(10 mins):
(Date:9/3/2020)... ... September 03, 2020 , ... Q&J Face Masks announced ... an aerosol and engineering lab, conducted tests on Q&J’s personal face mask that ... than many other masks. Q&J face masks have both mechanical filtering and electrostatic ...
(Date:9/3/2020)... N.Y. (PRWEB) , ... September 03, 2020 , ... ... students, teachers and staff can safely return to schools and classrooms across the ... has added TEMPE to its technology product line. TEMPE is a non-contact, wall-mounted ...
(Date:9/2/2020)... ... September 02, 2020 , ... ... Penetration Technology, LLC, (APT) a Texas- and Indiana-based company ( http://www.aptt3x.com ) ... Counter (OTC) products, was today provided results of an independent laboratory evaluation ...
Breaking Medicine Technology:
Cached News: